Rochester, MN, USA — Resoundant, Inc. is pleased to once again be exhibiting at the International Liver Congress™ (ILC), hosted by the European Association for the Study of the Liver (EASL), being held on April 19 — 23, 2017, at the RAI Exhibition and Convention Centre in Amsterdam, The Netherlands. "The International Liver Congress™ is an important scientific and clinical meeting," said Richard L. Ehman, MD, CEO of Resoundant, Inc, professor of Radiology and the Blanche R. & Richard J. Erlanger Professor of Medical Research at the Mayo Clinic. “Once again, we are honored to be part of the event.”
Resoundant, Inc. will be exhibiting at Booth #184, where attendees can learn more about how liver MR Elastography (MRE) can benefit their patients and practices. Through dozens of clinical studies throughout the years, MRE has been shown to have the highest clinical accuracy for staging liver fibrosis.
While MR Elastography is already available to clinicians at over 800 Radiology and imaging centers across the globe, increasing demand from the Hepatology community is expected to push that figure to well over 1,000 by the end of the year.
“Year over year demand for MRE from our global partners (GE Healthcare, Philips Healthcare, and Siemens Healthineers) has more than doubled,” said Troy Ziegler, Chief Operating Officer at Resoundant. “We have already accelerated our production schedule beyond recent forecasts and are planning to do so again. We think this is a tremendous sign that adoption of MRE is very robust, and that more and more Hepatologists are accepting MRE as the most reliable and accurate diagnostic tool for liver fibrosis available.”
“Hepatologists are increasingly leveraging advanced diagnostics to develop the most personalized care plans possible,” added Dr. Ehman. "For us, The International Liver Congress™ is an opportunity to show clinicians how MR elastography can improve diagnostic confidence in assessing liver disease”
SELECT MRE ABSTRACT AND POSTER LIST
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Alina M. Allen, et al.
Conclusions: This preliminary data shows that the Hepatogram can accurately predict NAS score and represents a promising alternative to liver biopsy for NASH diagnosis and monitoring.
Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease
Author: Charlie C. Park, et al.
Conclusions: In a prospective, cross-sectional study of more than 100 patients, we found MRE to be more accurate than TE in identification of liver fibrosis (stage 1 or more), using biopsy assessment as the standard. MRI-PDFF is more accurate than CAP in detecting all grades of steatosis in patients with NAFLD.
Diagnostic accuracy of magnetic resonance elastography with liver fibrosis assessment in chronic viral hepatitis patients
Hana Park, et al.
Conclusions: MRE is a reliable noninvasive method for identifying significant fibrosis and cirrhosis in patient with chronic viral hepatitis. It has better diagnostic performance than TE for the diagnosis of significant fibrosis and cirrhosis.
Prospective prevalence study of adult NAFLD/NASH utilizing multi-modality imaging compared with liver bopsy
Stephen A. Harrison
Conclusions: Using several novel FS or MRI-based imaging markers, this study confirms the high prevalence of NAFLD and NASH among adults in south Texas. FS-CAP and MRI-PDFF are very good imaging modalities to non-invasively assess liver fat and FS-LSM/MRE are very good imaging modalities to non-invasively assess fibrosis in NAFLD.
About Resoundant, Inc.
Resoundant, Inc is a medical technology company dedicated to improving patient care and diagnosis accuracy by making Magnetic Resonance Elastography (MRE) available around the world. We are based in Rochester, MN and were founded by Mayo Foundation for Medical Education & Research, Mayo Clinic physicians and researchers.
For more information, go to www.resoundant.com
Chief Operating Officer
Sales & Channel Partnerships